Filing Details
- Accession Number:
- 0001209191-23-032726
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-26 21:00:56
- Reporting Period:
- 2023-05-25
- Accepted Time:
- 2023-05-26 21:00:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 899460 | Mannkind Corp | MNKD | Pharmaceutical Preparations (2834) | 133607736 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1674282 | Michael Castagna | 1 Casper Street Danbury CT 06810 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, $.01 Par Value | Acquisiton | 2023-05-25 | 345,000 | $0.00 | 2,676,735 | No | 4 | A | Direct | |
| Common Stock, $.01 Par Value | Disposition | 2023-05-25 | 75,000 | $4.59 | 2,601,735 | No | 4 | S | Direct | |
| Common Stock, $.01 Par Value | Disposition | 2023-05-26 | 75,000 | $4.50 | 2,526,735 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock, $.01 Par Value | Performance Restricted Stock Unit | Acquisiton | 2023-05-25 | 422,000 | $0.00 | 422,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 422,000 | No | 4 | A | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.
- Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested.
- Transaction occurred pursuant to a Rule 10B5-1 Plan adopted on December 5, 2022.
- The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above.
Billionaire Hedge Funds
